Understanding a Therapeutic “Paradox” for Treating Thrombo-Vascular Complications in Kidney Disease
Researchers have discovered a potential treatment target to prevent chronic kidney disease patients from developing blood clots without causing bleeding complications – an unwanted and perplexing side effect. They say the strategy offers a much-needed therapeutic alternative to standard-of-care heparin, which throws off the finely-tuned balance between pro-clotting and anticoagulant factors in blood vessels that work to keep fluid flowing while protecting against excessive bleeding after injuries.
Seeking to better understand what causes clotting, researchers from BUSM developed an experimental model for late-stage kidney disease. The researchers narrowed in on a regulatory protein named STUB1 that interacts with a blood vessel wall component called tissue factor (TF), which triggers the clotting cascade. STUB1 belongs to a class of molecules called ubiquitin ligases that tag proteins (like TF) to be broken down for recycling. Interestingly, boosting STUB1 decreased the abundance of TF and prevented blood vessel blockages in these models without causing excessive bleeding.
In samples from human patients, the researchers noted an inverse correlation between the amounts of TF and STUB1. They say that enhancing either the production of STUB1 or its interaction with TF could both be viable options for addressing excessive clotting in kidney disease. They further add that several dynamic cellular events influence the blood clotting processes, and their precise quantification is required to determine a patient’s overall risk of developing blood clots, and allow individualization of therapy.
“Our work establishes a new means of minimizing the uremic hyperthrombotic phenotype without altering the hemostatic balance, a long-sought-after combination in patients with chronic kidney disease,“ explained corresponding author Vipul Chitalia, MD, PhD, associate professor of medicine at BUSM. “Diverse expertise and a collaborative spirit of trainees and investigators, including Drs. Shashar, Belghasem, Kolachalama and Matsuura allowed this discovery to matriculate, yet, it is important to remember that cellular and murine-based studies require further confirmation in humans, ” said co-senior investigator Katya Ravid, DSc, professor of medicine and biochemistry at BUSM.
This innovative work was published in Science Translational Medicine, featured on the journal’s cover, and primarily supported by NIH grants to Vipul Chitalia and Katya Ravid and by the Evans Center for Interdisciplinary Biomedical Research ARC on Thrombosis.